Print

Purpose

The primary objective of the study is to evaluate the reduction of LDL-C by evinacumab in comparison to placebo after 16 weeks in patients with primary hypercholesterolemia (HeFH, or non-HeFH with a history of clinical ASCVD) with persistent hypercholesterolemia despite receiving maximally-tolerated LMT. Persistent hypercholesterolemia is defined as LDL-C ≥70 mg/dL (1.81 mmol/L) for those patients with clinical ASCVD and LDL-C ≥100 mg/dL (2.59 mmol/L) for those patients without clinical ASCVD.

Condition

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Men and women, ages 18 through 80 at the screening visit 2. Diagnosis of primary hypercholesterolemia, either HeFH or non-HeFH with clinical ASCVD 3. A history of clinical ASCVD, for those patients who are non-HeFH. 4. Receiving a stable maximally tolerated statin (± ezetimibe) for at least 4 weeks at screening 5. For those patients with HeFH who are not receiving a statin at screening, documentation of inability to tolerate at least 2 statins. 6. Receiving alirocumab 150 mg SC Q2W, OR evolocumab 140 mg SC Q2W or 420 mg SC Q4W for at least 8 weeks prior to the screening visit 7. For those patients with a history of clinical ASCVD, serum LDL-C ≥ 70 mg/dL at screening (1 repeat lab is allowed) 8. For those patients without a history of clinical ASCVD, serum LDL-C ≥ 100 mg/dL at screening (1 repeat lab is allowed) 9. Provide signed informed consent

Exclusion Criteria

  1. Known history of homozygous FH (clinically, or by previous genotyping) 2. Presence of any clinically significant uncontrolled endocrine disease known to influence serum lipids or lipoproteins 3. Newly diagnosed diabetes (within 3 months prior to screening) 4. Use of thyroid medications (except for replacement therapy which has been stable for at least 12 weeks before screening) 5. Laboratory findings during screening period (not including randomization labs): 1. Triglycerides > 400 mg/dL (> 4.52 mmol/L) for patients without a known history of diabetes mellitus; OR Triglycerides > 300 mg/dL (> 3.39 mmol/L) for patients with a known history of diabetes mellitus 2. Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody (associated with a positive HCV ribonucleic acid [RNA] polymerase chain reaction) 3. Positive serum beta-human chorionic gonadotropin or urine pregnancy test in women of childbearing potential 4. Estimated glomerular filtration rate < 30 mL/min/1.73 m^2 5. TSH > 1.5 x ULN 6. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN 6. Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg at screening visit or time of randomization 7. History of heart failure (New York Heart Association [NYHA] Class III-IV) within 12 months before screening 8. History of MI, unstable angina leading to hospitalization, CABG surgery, PCI, uncontrolled cardiac arrhythmia, carotid surgery or stenting, stroke, TIA, carotid revascularization, endovascular procedure or surgical intervention for peripheral vascular disease within 3 months prior screening 9. History of cancer within the past 5 years (except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer) 10. Having received LDL apheresis within 2 months before screening 11. Pregnant or breast-feeding women 12. Women of childbearing potential who are unwilling to practice a highly effective birth control method 13. Men who are sexually active with women of childbearing potential (WOCBP) and are unwilling to consistently use condoms during the study drug treatment period regardless of vasectomy status.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Group A: dosing regimen 1 		SC Evinacumab QW for 16 weeks
  • Drug: Evinacumab
    SC or IV administration
    Other names:
    • REGN1500
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group A: dosing regimen 2 		SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
  • Drug: Evinacumab
    SC or IV administration
    Other names:
    • REGN1500
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group A: dosing regimen 3 		SC Evinacumab QW for 16 weeks
  • Drug: Evinacumab
    SC or IV administration
    Other names:
    • REGN1500
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group A: matching placebo 		Placebo SC QW for 16 weeks
  • Drug: Matching placebo
    SC or IV administration
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group B: dosing regimen 1 		Intravenous (IV) Evinacumab Q4W for 24 weeks
  • Drug: Evinacumab
    SC or IV administration
    Other names:
    • REGN1500
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group B: dosing regimen 2 		IV Evinacumab Q4W for 24 weeks
  • Drug: Evinacumab
    SC or IV administration
    Other names:
    • REGN1500
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
Experimental
Group B: matching placebo 		Placebo IV Q4W for 24 weeks
  • Drug: Matching placebo
    SC or IV administration
  • Other: Background Lipid Modifying Therapy (LMT)
    All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.

More Details

Status
Completed
Sponsor
Regeneron Pharmaceuticals

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.